This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene to Invest $25M in New Soon-Shiong Healthcare Venture

06/05/14 - 01:42 PM EDT

Celgene CELG is once again partnering with billionaire drug executive Patrick Soon-Shiong. Next Tuesday, Celgene will announce a $25 million investment in NantHealth, a healthcare technology company founded Soon-Shiong, TheStreet has learned.


Northwest Bio Fuzzier on Cancer Vaccine Study Patient Enrollment

06/05/14 - 08:30 AM EDT

On Wednesday afternoon during a presentation at an investor conference, Northwest Bio CEO Linda Powers once again offered conflicting language on the timeline for enrollment of 312 glioblastoma patients in the phase III study of the experimental cancer vaccine DC-Vax.


Prosensa to Seek U.S. Approval for DMD Drug

06/03/14 - 07:39 AM EDT

Prepare now for the most epic, two-day FDA advisory panel sometime in the middle of 2015: Prosensa and Sarepta Therapeutics with their respective and competitive exon 51-skipping therapies against Duchenne muscular dystrophy (DMD).


Incyte's 'IDO' Cancer Immunotherapy Causes Investor Scrum at ASCO '14

06/02/14 - 03:20 PM EDT

We just got our first look at the clinical activity of Incyte's immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with Bristol-Myers Squibb's BMY Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane.


If You Build It, They Will Chuckle: Northwest Bio's Super-Sized ASCO '14 Booth

06/02/14 - 11:23 AM EDT

I'm sure Northwest Bio thought it would raise its profile with a booth the size of a small Illinois town, but from an investors' perspective, the company was simply the brunt of guffaws over the weekend for wasting a ridiculous amount of money.


ASCO '14: Sell-Side Buzz Over Big Pharma Immuno-Oncology Pipelines

06/02/14 - 06:54 AM EDT

It's Monday, so we get to see how investors react to a full weekend's worth of cancer drug data presentations at the American Society of Clinical Oncology (ASCO) annual meeting.


ASCO '14: What's on Tap for Saturday

05/30/14 - 02:01 PM EDT

Featured data presentations from Eli Lilly, Pharmacyclics and Clovis Oncology on the Saturday menu for the biggest cancer conference in the world.


A Greek Lawyer Managing a Little-Known Investment Fund Wants to Buy Vivus for $640 Million

05/28/14 - 10:37 AM EDT

Aspen Investments and Zoi Potsi, a resident of Cyprus, declared a 9.65% ownership stake in struggling obesity pill marketer Vivus this morning and say they want to buy the rest of the company for $640 million.


Cancer Patients Aren't Responding to Northwest Bio's DCVax-Direct

05/27/14 - 06:07 PM EDT

The tumor response rate attributable to Northwest Biotherapeutics DCVax-Direct is zero. None of the 19 patients with advanced, metastatic cancers have responded to treatment with DCVax-Direct in an ongoing phase I clinical study.


NYSE Places Provectus Listing Status Under Review

05/27/14 - 09:48 AM EDT

The New York Stock Exchange has placed Provectus' listing status under review, following Friday's PV-10 Breakthrough Therapy Designation debacle. The stock may re-open at some point today, or may not. And if Provectus does trade today, it may not trade for long.


Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -


DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs